| Insiders | Shares | % | Avg Price | Total $ | |
|---|---|---|---|---|---|
| Buys | 3 | +30.6 K | 100% | $3.67 | +$112 K |
| Sells | 0 | ||||
| Net | +3 | +30.6 K | 100% | +$112 K |
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Report Date |
|---|---|---|---|---|---|
| Joseph Todisco | Chief Executive Officer, Director | $1.68 M | +$87.8 K | +5.5% | May 10, 2024 |
| Myron Kaplan | Director | $680 K | Mar 5, 2024 | ||
| Steven W. Lefkowitz | Director | $374 K | Mar 5, 2024 | ||
| Erin Mistry | Chief Commercial Officer | $175 K | +$4 K | +2.34% | Jan 12, 2024 |
| Beth Zelnick | Chief Legal Officer | $174 K | Dec 12, 2023 | ||
| Matthew T. David | Chief Financial Officer | $166 K | Jan 12, 2024 | ||
| Elizabeth Masson-Hurlburt | EVP, Head of Clinical Ops. | $158 K | Jan 12, 2024 | ||
| Alan W. Dunton | Director | $52.9 K | +$20.3 K | +62% | Mar 5, 2024 |
| Robert A. Stewart | Director | $38.2 K | Mar 5, 2024 | ||
| Paulo F. Costa | Director | $34.7 K | May 17, 2023 | ||
| Phoebe Mounts | General Counsel | $25 K | Jan 14, 2023 | ||
| Gregory Scott Duncan | Director | Mar 5, 2024 | |||
| Janet Dillione | Director | Mar 5, 2024 | |||
| Thomas Nusbickel | EVP, Chief Commercial Officer | Feb 18, 2022 |
| Insider | Class | Transaction | % | Value $ | Price $ | Shares | Shares Owned | Date | Ownership |
|---|